Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Zenz

Showing results (21-30 of 183) with videos related to

Pageof 19
Sort By:
Current Hematologic Malignancy Reports|January 13, 2012
Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Leopold Sellner, Sascha Dietrich, Peter Dreger, et al.
Best Practice & Research. Clinical Haematology|July 13, 2010
Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)Thorsten Zenz, Stefan Fröhling, Daniel Mertens, et al.
Nature Reviews. Cancer|December 4, 2009
From pathogenesis to treatment of chronic lymphocytic leukaemiaThorsten Zenz, Daniel Mertens, Ralf Küppers, et al.
Haematologica|December 8, 2010
Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2Angela Schulz, Grischa Toedt, Thorsten Zenz, et al.
Haematologica|May 30, 2008
The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemiaThorsten Zenz, Sonja Häbe, Axel Benner, et al.
British Journal of Haematology|June 10, 2010
SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL)Angela Philippen, Susanne Diener, Thorsten Zenz, et al.
Leukemia & Lymphoma|October 26, 2011
Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemiaMartina Seiffert, Sascha Dietrich, Alexander Jethwa, et al.
Oncoimmunology|May 8, 2015
Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cellsSrinivas Mamidi, Simon Höne, Claudia Teufel, et al.
Haematologica|February 23, 2019
Energy metabolism is co-determined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivityJunyan Lu, Martin Böttcher, Tatjana Walther, et al.
Blood|March 8, 2012
Risk categories and refractory CLL in the era of chemoimmunotherapyThorsten Zenz, John G Gribben, Michael Hallek, et al.
Pageof 19

Showing results (21-30 of 183) with videos related to

Sort By:
Pageof 19
Current Hematologic Malignancy Reports|January 13, 2012
Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Leopold Sellner, Sascha Dietrich, Peter Dreger, et al.
Best Practice & Research. Clinical Haematology|July 13, 2010
Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)Thorsten Zenz, Stefan Fröhling, Daniel Mertens, et al.
Nature Reviews. Cancer|December 4, 2009
From pathogenesis to treatment of chronic lymphocytic leukaemiaThorsten Zenz, Daniel Mertens, Ralf Küppers, et al.
Haematologica|December 8, 2010
Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2Angela Schulz, Grischa Toedt, Thorsten Zenz, et al.
Haematologica|May 30, 2008
The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemiaThorsten Zenz, Sonja Häbe, Axel Benner, et al.
British Journal of Haematology|June 10, 2010
SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL)Angela Philippen, Susanne Diener, Thorsten Zenz, et al.
Leukemia & Lymphoma|October 26, 2011
Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemiaMartina Seiffert, Sascha Dietrich, Alexander Jethwa, et al.
Oncoimmunology|May 8, 2015
Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cellsSrinivas Mamidi, Simon Höne, Claudia Teufel, et al.
Haematologica|February 23, 2019
Energy metabolism is co-determined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivityJunyan Lu, Martin Böttcher, Tatjana Walther, et al.
Blood|March 8, 2012
Risk categories and refractory CLL in the era of chemoimmunotherapyThorsten Zenz, John G Gribben, Michael Hallek, et al.
Pageof 19